|1.||Marcellin, Patrick: 15 articles (08/2013 - 02/2003)|
|2.||Brosgart, Carol L: 13 articles (06/2011 - 02/2003)|
|3.||Xiong, Shelly: 12 articles (10/2008 - 08/2002)|
|4.||Rousseau, Franck: 10 articles (06/2012 - 01/2007)|
|5.||Chang, Ting-Tsung: 9 articles (04/2011 - 02/2003)|
|6.||Heathcote, E Jenny: 9 articles (01/2011 - 02/2003)|
|7.||Zoulim, Fabien: 9 articles (10/2010 - 06/2004)|
|8.||De Clercq, Erik: 8 articles (11/2015 - 10/2003)|
|9.||Kumada, Hiromitsu: 8 articles (06/2014 - 01/2004)|
|10.||Suzuki, Fumitaka: 8 articles (06/2014 - 01/2004)|
|1.||Chronic Hepatitis B
01/01/2012 - "Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB). "
01/01/2003 - "Existing treatment options for patients with chronic hepatitis B are limited in both number and effectiveness; the proven efficacy, good tolerability profile and apparently low potential for resistance of adefovir dipivoxil make it a promising new option in the management of this disease."
01/01/2012 - "We developed an improved reverse dot hybridization test for simple and rapid detection of the rtA181V/T and rtN236T mutations associated with adefovir dipivoxil resistance in chronic hepatitis B patients. "
03/01/2004 - "Adefovir dipivoxil, a nucleotide analogue recently approved by the Food and Drug Administration for the treatment of chronic hepatitis B, is effective against hepatitis B virus (HBV) but has been associated with renal toxicity at high doses. "
11/01/2004 - "Effective phosphorylation coupled with a long intracellular half-life and small competing dATP pool sizes in primary hepatocytes forms the cellular metabolic basis for the efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B."
05/01/2011 - "Large clinical trials advocated the safety of adefovir dipivoxil at a daily dose of 10 mg, the standard dose given to patients with hepatitis B. "
09/01/2003 - "Recent studies of adefovir dipivoxil for hepatitis B."
03/01/2013 - "Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran."
02/15/2012 - "A 1995 μmol/L concentration of the commercially-available hepatitis B drug, adefovir dipivoxil (ADV), was required to achieve 50% cytotoxicity against cultured cells (CC(50)) by day nine; in contrast, only 1747 μmol/L of Compound 1 was required for the same result. "
02/14/2008 - "Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. "
03/01/2005 - "Based on this preliminary result, adefovir dipivoxil seems to be an effective and safe antiviral agent leading to viral inhibition and clinical improvement in post-LT patients with recurrent or de novo HBV infection."
11/01/2003 - "However, a longer follow-up is needed to establish the long term safety and efficacy of adefovir dipivoxil in patients with chronic HBV infection."
01/01/2009 - "Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report."
08/01/2007 - "Adefovir dipivoxil (ADV)-resistant mutations have been identified in treating hepatitis B virus (HBV) infection. "
03/02/2004 - "We have found that adefovir dipivoxil, a drug approved to treat chronic infection of hepatitis B virus, effectively inhibits EF-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages. "
|4.||Liver Diseases (Liver Disease)
11/01/2003 - "[Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases]."
08/01/2004 - "[Safety and efficacy of of adefovir dipivoxil in the treatment of patients with chronic hepatitis B-related liver disease]."
02/01/2006 - "However, some patients may experience a hepatitis flare with the emergence of YMDD mutants resulting in progressive worsening of liver disease, and should be referred for "rescue" therapy with other nucleoside/nucleotide analogues such as adefovir dipivoxil."
08/01/2004 - "All these characteristics make adefovir dipivoxil an important drug for the treatment of hepatitis B virus infection and an excellent candidate for long-term maintenance therapy in chronic viral B liver disease."
10/01/2005 - "Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus."
12/01/2006 - "Ishak fibrosis scores improved compared with baseline in 35%, 55%, and 71% of patients after 48, 192, and 240 weeks of adefovir dipivoxil, respectively. "
03/01/2012 - "To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil. "
03/01/2012 - "[Experimental study on effect of dahuang zhechong wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B]."
07/01/2009 - "[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]."
11/01/2007 - "[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period]."
|2.||Hepatitis B e Antigens
|6.||DNA (Deoxyribonucleic Acid)
|9.||tenofovir disoproxil (Viread)
|2.||Stem Cell Transplantation
|3.||Transplantation (Transplant Recipients)